KAYO 1732
Alternative Names: KAYO-1732Latest Information Update: 31 Mar 2025
At a glance
- Originator KayoThera
- Class Small molecules
- Mechanism of Action Aldehyde dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 24 Mar 2025 Preclinical trials in Type 2 diabetes mellitus in USA (PO) (Kayothera pipeline, March 2025)